ATE430161T1 - Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung - Google Patents

Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung

Info

Publication number
ATE430161T1
ATE430161T1 AT01980380T AT01980380T ATE430161T1 AT E430161 T1 ATE430161 T1 AT E430161T1 AT 01980380 T AT01980380 T AT 01980380T AT 01980380 T AT01980380 T AT 01980380T AT E430161 T1 ATE430161 T1 AT E430161T1
Authority
AT
Austria
Prior art keywords
peptide
hsp70
stimulates
present
cell activity
Prior art date
Application number
AT01980380T
Other languages
English (en)
Inventor
Gabriele Multhoff
Original Assignee
Multimmune Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multimmune Gmbh filed Critical Multimmune Gmbh
Application granted granted Critical
Publication of ATE430161T1 publication Critical patent/ATE430161T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01980380T 2000-09-13 2001-09-13 Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung ATE430161T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00119933 2000-09-13
PCT/EP2001/010593 WO2002022656A2 (en) 2000-09-13 2001-09-13 An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
BE2009/0695A BE1019732A4 (fr) 2000-09-13 2009-11-12 Peptide de hsp70 simulant l'activite de cellules tueuses naturelles (nk) et ses utilisations.

Publications (1)

Publication Number Publication Date
ATE430161T1 true ATE430161T1 (de) 2009-05-15

Family

ID=47436345

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980380T ATE430161T1 (de) 2000-09-13 2001-09-13 Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung

Country Status (8)

Country Link
US (2) US7517948B2 (de)
EP (1) EP1319023B8 (de)
AT (1) ATE430161T1 (de)
AU (1) AU2002212236A1 (de)
BE (1) BE1019732A4 (de)
DE (1) DE60138558D1 (de)
ES (1) ES2326114T3 (de)
WO (1) WO2002022656A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517948B2 (en) * 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof
IL148401A0 (en) * 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
ES2340270T3 (es) * 2002-08-23 2010-06-01 Gabriele Prof. Dr. Multhoff Granzima b dependiente de peptidos hsp70/hsp70 como inductora de apoptosis en celulas tumorales.
EP1695093A1 (de) * 2003-12-05 2006-08-30 multimmune GmbH Verbindungen und verfahren zur behandlung und diagnose von neoplastischen und infektiösen krankheiten
ES2484340T3 (es) * 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
CA2702370A1 (en) * 2006-11-14 2008-05-22 Ralf Dressel Compositions and methods for immunotherapy
GB0705626D0 (en) * 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
EP2484371B1 (de) 2008-06-26 2014-12-17 Orphazyme APS Verwendung von HSP70 als Regler der enzymatischen Aktivität
WO2012023631A1 (ja) * 2010-08-19 2012-02-23 株式会社Eci ヒートショックプロテイン（ｈｓｐ）とｅｃｉ３０１ポリペプチドを含む癌細胞の増殖を抑制するための医薬組成物ならびにそれを用いた癌の治療方法
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
US20160000777A1 (en) * 2013-02-21 2016-01-07 University Of Rochester Methods of using histamine receptor agonists and antagonists
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
WO2016120218A1 (en) 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
EP3797794A1 (de) 2015-04-07 2021-03-31 Cytlimic Inc. Medizin enthaltend einen toll like rezeptor 3 agonisten und ein lag-3 protein
CA3017356A1 (en) 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
SI3448382T1 (sl) 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
WO2018037042A1 (en) * 2016-08-23 2018-03-01 Aimvion A/S Novel immunostimulating peptides
CN106317216B (zh) * 2016-09-21 2019-07-19 南京农业大学 一种促进h9n2禽流感疫苗免疫效果的活性肽及应用
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CA3071217A1 (en) 2017-08-31 2019-03-07 Multimmune Gmbh Hsp70 based combination therapy
WO2022106614A1 (en) 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN121518391B (zh) * 2026-01-16 2026-04-28 广州赛琅生物技术有限公司 一种基于多因子联合诱导的nk细胞培养方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein
ES2246566T5 (es) 1998-03-27 2010-10-26 Gabriele Prof. Dr. Multhoff Aplicacion de proteinas hsp70.
CN1057363C (zh) 1998-07-10 2000-10-11 贺德新 一种液压挤扩装置
CA2352286C (en) 1998-11-24 2011-07-12 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kd heat shock protein
US7517948B2 (en) * 2000-09-13 2009-04-14 Multimmune Gmbh Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof

Also Published As

Publication number Publication date
EP1319023B8 (de) 2009-07-15
WO2002022656A3 (en) 2002-09-26
AU2002212236A1 (en) 2002-03-26
US7517948B2 (en) 2009-04-14
WO2002022656A2 (en) 2002-03-21
EP1319023B1 (de) 2009-04-29
BE1019732A4 (fr) 2012-12-04
US20090239802A1 (en) 2009-09-24
EP1319023A2 (de) 2003-06-18
DE60138558D1 (de) 2009-06-10
US20040063173A1 (en) 2004-04-01
ES2326114T3 (es) 2009-10-01
US7745399B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
WO2003064449A3 (en) Bioactive keratin peptides
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
EP2014678A3 (de) KDR-Peptide und Impfstoffe damit
WO2002044320A3 (en) Human elongase genes and uses thereof
TW200407425A (en) Human coagulation factor VII polypeptides
NL300830I1 (nl) Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
DE602006020898D1 (de) Peptide zur förderung des haarwachstums und zur verbesserung von falten und kosmetische zusammensetzungen, die diese enthalten
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
MX2025009372A (es) Proteinas/peptidos de fusion, metodos y usos de los mismos
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
UA84831C2 (ru) Производные фактора коагуляции vii
ATE490324T1 (de) Nukleinsäuren kodierend für polypeptide mit chips aktivität
TR199902866T2 (xx) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler.
CY1109617T1 (el) Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
ATE338063T1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers
DK0811068T3 (da) Humane DNase I varianter
ATE400288T1 (de) Peptide mit hohem cysteingehalt
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1319023

Country of ref document: EP